MONITOR‐GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy‐induced/febrile neutropenia prophylaxis

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|100|3|241-246

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.100, Iss.3, 2018-03, pp. : 241-246

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns

By  

Oncology Research and Treatment, Vol. 38, Iss. 4, 2015-03 ,pp. : 146-152

Karger

Access to resources Recommend Favorite

Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma

By  

Oncology Research and Treatment, Vol. 32, Iss. 10, 2009-09 ,pp. : 599-604

Karger

Access to resources Recommend Favorite

Clinical Outcomes and Cost‐effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer

By  

THE BREAST JOURNAL, Vol. 21, Iss. 6, 2015-11 ,pp. : 658-664

John Wiley & Sons Inc

Access to resources Recommend Favorite

G-CSF in the Prevention of Febrile Neutropenia in Chemotherapy in Breast Cancer Patients

By  

Oncology Research and Treatment, Vol. 29, Iss. 4, 2006-03 ,pp. : 171-178

Karger

Access to resources Recommend Favorite

Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia

By  

Reviews on Recent Clinical Trials, Vol. 11, Iss. 1, 2016-03 ,pp. : 72-76

Bentham Science Publishers

Access to resources Recommend Favorite